On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the ?Company?) entered into a Transition and Separation Agreement (the ?Agreement?) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024. Dr. Wilbur's departure is not due to any disagreement with the Company?s management team, operations, financial statements, policies or procedures.